Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target
Benzinga · 6d ago
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), Legend Biotech (LEGN) and Celldex (CLDX)
TipRanks · 6d ago
Blueprint Medicines Receives Sell Rating Amidst Modest Polypharmacy Reduction and Negative Share Price Projections
TipRanks · 6d ago
Buy Rating Affirmed for Blueprint Medicines on Strong Ayvakit Clinical Performance and Promising Pipeline
TipRanks · 6d ago
Weekly Report: what happened at BPMC last week (0219-0223)?
Weekly Report · 6d ago
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), AMN Healthcare Services (AMN) and Ironwood Pharma (IRWD)
TipRanks · 6d ago
Blueprint Medicines: Sell Rating Justified by Gavreto Divestiture and Strategic Shift
Leerink Partners analyst Andrew Berens has maintained a Sell rating on Blueprint Medicines stock. The drug divestiture of Gavreto to Rigel Pharmaceuticals for a modest sum highlights the drug's lackluster commercial performance. The company's price has increased 74.30% in the past six months.
TipRanks · 6d ago
Stifel Nicolaus Keeps Their Buy Rating on Blueprint Medicines (BPMC)
TipRanks · 02/23 12:21
Barclays Sticks to Its Hold Rating for Blueprint Medicines (BPMC)
TipRanks · 02/23 08:15
Blueprint Medicines Divests GAVRETO Rights to Rigel
Rigel Pharmaceuticals has acquired the U.S. Rights to GAVRETO, a cancer treatment drug, from Blueprint Medicines Corporation for an initial $15 million. The deal is expected to reduce Blueprint's operating expenses. Blueprint is ending its global collaboration with Roche and will phase out the drug's development and marketing outside the US.
TipRanks · 02/22 13:33
(BPMC) - Analyzing Blueprint Medicines's Short Interest
Blueprint Medicines's short percent of float has risen 5.37% since its last report. The company has 4.60 million shares sold short, which is 10.2% of its float. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 02/20 20:45
Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Blueprint Medicines' Ayvakit shows strong performance in the ISM market, with revenue projections increased to $2 billion. The company has a strong cash position despite a high burn rate. The stock is up 64% since my "buy" recommendation in late October.
Seeking Alpha · 02/20 17:17
Blueprint Medicines Corporation's (NASDAQ:BPMC) Path To Profitability
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders. The company posted a loss of US$507m for its most recent financial year. Blueprint Medicines is projected to turn a profit in 2026. Analyst expectations for the company suggest the company will grow at a rate of 66%. The company has a debt-to-equity ratio of over 2x.
Simply Wall St · 02/19 19:48
Weekly Report: what happened at BPMC last week (0212-0216)?
Weekly Report · 02/19 09:31
Blueprint Medicines Sell Rating: Assessing Ayvakit’s Market Potential and Financial Concerns
Leerink Partners analyst Andrew Berens has maintained their bearish stance on Blueprint Medicines with a Sell rating on February 16. Berens is concerned about the sustainability of the drug Ayvakit's early success. The company's guidance for 2024 also raises questions about the company's future prospects.
TipRanks · 02/19 04:45
Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings
NASDAQ · 02/16 20:30
Webull provides a variety of real-time BPMC stock news. You can receive the latest news about Blueprint Medicines Corp through multiple platforms. This information may help you make smarter investment decisions.
About BPMC
Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.